Edition:
United Kingdom

Qiagen NV (QIA.DE)

QIA.DE on Xetra

26.53EUR
12:04pm GMT
Change (% chg)

€0.07 (+0.26%)
Prev Close
€26.46
Open
€26.50
Day's High
€26.58
Day's Low
€26.38
Volume
76,442
Avg. Vol
512,377
52-wk High
€31.52
52-wk Low
€25.41

Chart for

About

QIAGEN N.V. (QIAGEN) is a holding company. The Company is engaged in providing Sample to Insight solutions that transform biological samples into molecular insights. Its Sample to Insight solutions integrate sample and assay technologies, bioinformatics and automation systems. Its sample technologies are used for isolating and... (more)

Overall

Beta: 0.60
Market Cap(Mil.): €6,716.56
Shares Outstanding(Mil.): 230.83
Dividend: 1.01
Yield (%): --

Financials

  Industry Sector
P/E (TTM): -- 88.65 16.44
EPS (TTM): -- -- --
ROI: -- 2.35 10.62
ROE: -- 2.95 14.20

BRIEF-Qiagen To Transfer U.S. Listing Of Global Shares To Nyse

* QIAGEN TO TRANSFER U.S. LISTING OF GLOBAL SHARES TO NYSE Source text for Eikon: Further company coverage:

08 Dec 2017

As Brexit looms, UK pitches new industry plan, wins support from Merck, Qiagen

LONDON Britain pitched a new strategy for industry on Monday, pledging greater state intervention to tackle weak productivity and to help the world's sixth largest economy cope with the upheaval of leaving the European Union.

27 Nov 2017

As Brexit looms, UK pitches new industry plan, wins support from Merck, Qiagen

LONDON Britain pitched a new strategy for industry on Monday, pledging greater state intervention to tackle weak productivity and to help the world's sixth largest economy cope with the upheaval of leaving the European Union.

27 Nov 2017

UPDATE 2-As Brexit looms, UK pitches new industry plan, wins support from Merck, Qiagen

* Drug industry remains concerned about Brexit impact (Adds Prime Minister, Business Secretary comments, reaction)

27 Nov 2017

BRIEF-Qiagen NV posts qtrly adjusted EPS $0.32‍​

* Qiagen NV - reaffirming 2017 adjusted EPS target of $1.25-1.27 cer before restructuring‍​

06 Nov 2017

BRIEF-Qiagen, Centogene to collaborate in bioinformatics for genetic diseases

* Qiagen and Centogene to collaborate in bioinformatics for genetic diseases

09 Oct 2017

BRIEF-Angle partners Qiagen in liquid biopsy portolio

* Partnership will seek to combine angle's parsortix system for harvesting circulating tumor cells with qiagen's liquid biopsy solution portfolio Source text for Eikon: Further company coverage: (Reporting By London Bureau)

11 Sep 2017

BRIEF-Bookrunner says Qiagen transaction priced at 30 pct premium on upsized $400 mln issue size

* BOOKRUNNER SAYS TRANSACTION WILL PRICE AT 0.50% COUPON AND 30% PREMIUM ON AN UPSIZED $400M ISSUE SIZE

06 Sep 2017

BRIEF-Bookrunner says orders below mids risk missing Qiagen deal

* BOOKRUNNER SAYS ORDERS BELOW MIDS RISK MISSING, FURTHER DETAILS TO FOLLOW ON BOOKS CLOSE IN QIAGEN DEAL Further company coverage: (Bengaluru Newsroom)

06 Sep 2017

BRIEF-Qiagen upgrades 2017 sales guidance after solid first half

* Says q2 net sales $349.0 million (+4% actual); adjusted net sales $349.6 million (+5% actual, +7% CER vs. +5-6% CER guidance)

27 Jul 2017

Earnings vs. Estimates